FrancophonIA/ELRC3.0 huggingface dataset:
English: Packaging Content Package sizeWithdrawal period
Estonian: Sisaldus Pakendi suurus
English: MA (EU) Number (Invented) name
Estonian: (Väljamõel dud) nimetus
English: Solution for injection
Estonian: Kontsentraat infusioonilahuse valmistamiseks
English: Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.
Estonian: Ravimiamet vaatab kogu võimaliku uue teabe igal aastal läbi ja vajaduse korral uuendab käesolevat kokkuvõtet.
English: Pixuvri can be given for up to six cycles.
Estonian: Pixuvrit võib anda kuni kuue tsüklina.
English: The side effects of the medicine were considered to be short term and manageable.
Estonian: Ravimi kõrvalnähte peeti lühiajaliseks ja kontrollitavaks.
English: The European Commission granted a conditional marketing authorisation valid throughout the European Union for Pixuvri on 10 May 2012.
Estonian: Euroopa Komisjon andis Pixuvri müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 10. mail 2012.
English: The full EPAR for Pixuvri can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Pixuvri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The main measure of effectiveness was the number patients who had a complete response to treatment.
Estonian: Peamine tulemusnäitaja oli täieliku ravivastusega patsientide arv.
English: In addition, patients treated with Pixuvri lived for longer without their disease getting worse.
Estonian: Peale selle elasid Pixuvriga ravitud patsiendid kauem, ilma et nende haigus oleks süvenenud.
English: The recommended dose is 50 mg/m2 given as an infusion into a vein over at least 60 minutes on days 1, 8 and 15 of a 28-day cycle.
Estonian: Soovitatav annus on 50 mg/m2 veenisisese infusioonina vähemalt 60 minuti jooksul 28-päevase ravitsükli 1., 8. ja 15. päeval.
English: This means that the cancer cells in non-Hodgkin's B cell lymphoma cannot divide and eventually die.
Estonian: See tähendab, et B-rakulise mitte-Hodgkini lümfoomi vähirakud ei saa jaguneda ja lõpuks hävivad.
English: This means that there is more evidence to come about the medicine, in particular its benefits in patients who have previously been treated with rituximab.
Estonian: See tähendab, et ravimi kohta oodatakse veel andmeid, eelkõige selle kasulikkuse kohta patsientidel, keda on varem ravitud rituksimaabiga.
English: The CHMP concluded that the benefits of Pixuvri are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee järeldas, et Pixuvri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The dose of Pixuvri is based on the patient's body surface area (calculated using the patient's height and weight).
Estonian: Pixuvri annus määratakse patsiendi kehapindala alusel (arvutatakse pikkuse ja kaalu järgi).
English: The most common side effects with Pixuvri (seen in more than 1 patient in 10) are neutropenia, leucopenia and lymphopenia (low levels of different types of white blood cells), thrombocytopenia (low levels of platelets in the blood), anaemia (low levels of red blood cells), nausea (feeling sick), vomiting, skin discolouration, hair loss, chromaturia (abnormal colouration of the urine) and asthenia (weakness).
Estonian: Pixuvri kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10-st) on neutropeenia, leukopeenia ja lümfopeenia (eri tüüpi valgeliblede vähesus), trombotsütopeenia (vereliistakute vähesus), aneemia (punaliblede vähesus), iiveldus, oksendamine, naha värvimuutus, juuste väljalangemine, kromatuuria (uriini ebanormaalne värvus) ja asteenia (nõrkus).
English: It must not be used in patients with severe liver problems and in patients whose bone marrow produces abnormally low levels of blood cells.
Estonian: Seda ravimit ei tohi kasutada ka patsiendid, kellel on tõsised maksaprobleemid, ja patsiendid, kelle luuüdi toodab ebanormaalselt vähe vererakke.
English: Pixuvri has been given ‘conditional approval'.
Estonian: Pixuvri müügiluba anti tingimusliku heakskiidu alusel.
English: Patients were given either six cycles of Pixuvri or another approved anticancer medicine chosen by their doctor.
Estonian: Patsientidele anti 6 tsüklit Pixuvrit või muud arsti valitud heakskiidetud vähiravimit.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pixuvri.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: EPAR summary for the public pixantrone
Estonian: Kokkuvõte üldsusele piksantroon
English: Pixuvri is a medicine that contains the active substance pixantrone.
Estonian: Pixuvri on ravim, mis sisaldab toimeainena piksantrooni.
English: In patients who develop side effects or who have very low blood levels of neutrophils (a type of white blood cell that fights infection) and platelets (components that help the blood to clot), the dose may have to be reduced or treatment may have to be delayed.
Estonian: Patsientidel, kellel tekivad kõrvalnähud või kellel on veres vähe neutrofiile (teatud infektsioonivastaseid valgeliblesid) ja trombotsüüte (vereliistakuid ehk hüübimist soodustavaid vererakke), võib olla vaja annust vähendada või tuleb ravi edasi lükata.
English: For more information about treatment with Pixuvri, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pixuvriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Patients receiving Pixuvri must not be given vaccines containing attenuated (weakened live) viruses.
Estonian: Pixuvrit kasutavatele patsientidele ei tohi manustada nõrgestatud (nõrku, kuid elusaid) viirusi sisaldavaid vaktsiine.
English: Other information about Pixuvri
Estonian: Muu teave Pixuvri kohta
English: The company that makes Pixuvri will carry out a study to further investigate the effects of using Pixuvri in patients who had received prior treatment with rituximab.
Estonian: Ettevõte, mis toodab Pixuvrit, korraldab uuringu Pixuvri toimete kohta patsientidel, keda on varem ravitud rituksimaabiga.
English: This is a cancer of the lymph tissue (part of the immune system) that affects a type of white blood cell called B lymphocytes, or B cells.
Estonian: See on lümfikoe (immuunsüsteemi osa) vähk, mis kahjustab teatud valgeliblesid B-lümfotsüüte ehk B-rakke.
English: What information is still awaited for Pixuvri?
Estonian: Mis teavet Pixuvri kohta veel oodatakse?
English: Why has Pixuvri been approved?
Estonian: Miks Pixuvri heaks kiideti?
English: Pixuvri must not be used in patients who are hypersensitive (allergic) to pixantrone or any of the other ingredients.
Estonian: Pixuvrit ei tohi kasutada patsiendid, kes on piksantrooni või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Pixuvri was compared with other chemotherapy treatments in one main study involving 140 adults with aggressive non-Hodgkin's B cell lymphoma, who had previously received at least two other treatments, and whose cancer had come back or had not responded to treatment.
Estonian: Pixuvrit võrreldi teiste keemiaravi ravimitega ühes põhiuuringus, milles osales 140 agressiivse B-rakulise mitte-Hodgkini lümfoomiga täiskasvanut, kes said enne vähemalt kahte muud ravimit ja kelle vähk oli retsidiveerunud või ei andnud muu ravi piisavat ravivastust.
English: It is available as a powder that is made up into a solution for infusion (a drip into a vein).
Estonian: Seda turustatakse pulbrina, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
English: However, the Committee noted that more data were needed on the benefits of Pixuvri in patients who have received previous treatment with rituximab (another medicine commonly used to treat lymphoma).
Estonian: Siiski tegi inimravimite komitee märkuse, et Pixuvri kasulikkuse kohta on vaja rohkem andmeid patsientidel, keda on varem ravitud rituksimaabiga (teine lümfoomi ravis sageli kasutatav ravim).
English: For the full list of all side effects reported with Pixuvri, see the package leaflet.
Estonian: Pixuvri kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Pixuvri was shown to be beneficial in patients with aggressive non-Hodgkin's B cell lymphoma: 20% of patients responded completely to Pixuvri (14 out of 70 patients) compared with 5.7% of patients receiving other agents (4 out of 70 patients).
Estonian: Pixuvriga tekkis täielik ravivastus 20%-l patsientidest (14 patsienti 70-st) võrreldes 5,7%-ga muud ravi saanud patsientidest (4 patsienti 70-st).
English: This is a summary of the European public assessment report (EPAR) for Pixuvri.
Estonian: See on ravimi Pixuvri Euroopa avaliku hindamisaruande kokkuvõte.
English: The CHMP also considered the seriousness of the disease and the lack of suitable alternative treatments for patients whose non-Hodgkin's B cell lymphoma has come back or has not responded to other chemotherapy treatments.
Estonian: Inimravimite komitee võttis arvesse ka haiguse raskusastet ja sobivate alternatiivsete ravimite puudumist patsientide jaoks, kelle agressiivne B-rakuline mitte-Hodgkini lümfoom retsidiveerus või kes ei saavutanud muude keemiaravi ravimitega piisavat ravivastust.
English: What is Pixuvri?
Estonian: Mis on Pixuvri?
English: The active substance in Pixuvri, pixantrone, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the group ‘anthracyclines'.
Estonian: Pixuvri toimeaine piksantroon on antratsükliinide (raku normaalset ainevahetust pärssivad ained) hulka kuuluv tsütotoksiline ravim (poolduvaid rakke, näiteks vähirakke hävitav ravim).
English: Pixuvri must be given by a doctor who has experience in the use of anticancer medicines and who has access to facilities for monitoring the patient.
Estonian: Pixuvrit tohib määrata üksnes vähiravis kogenud arst, kel on võimalik patsiendi seisukorda jälgida.
English: Pixuvri is used when the lymphoma is aggressive and has come back or has not responded to other chemotherapy treatments (medicines to treat cancer).
Estonian: Pixuvrit kasutatakse juhul, kui tegemist on agressiivse retsidiveerunud lümfoomiga või kui muu keemiaraviga (vähi ravimravi) ei ole tekkinud piisavat ravivastust.
English: What is the risk associated with Pixuvri?
Estonian: Mis riskid Pixuvriga kaasnevad?
English: Pixuvri is used to treat adult patients with non-Hodgkin's B cell lymphoma.
Estonian: Pixuvrit kasutatakse B-rakulise mitte-Hodgkini lümfoomiga täiskasvanud patsientide raviks.
English: The effects of Pixuvri were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Pixuvri toimet muude katsetega.
English: What is Pixuvri used for?
Estonian: Milleks Pixuvrit kasutatakse?
English: The CHMP concluded that patients with aggressive non-Hodgkin's B cell lymphoma had a better response to treatment with Pixuvri than other cancer treatments.
Estonian: Inimravimite komitee jõudis järeldusele, et Pixuvrit kasutavate agressiivse B-rakulise mitte-Hodgkini lümfoomiga patsientide ravivastus oli parem kui teisi ravimeid kasutanud patsientidel.
English: How is Pixuvri used?
Estonian: Kuidas Pixuvrit kasutatakse?
English: How does Pixuvri work?
Estonian: Kuidas Pixuvri toimib?
English: How has Pixuvri been studied?
Estonian: Kuidas Pixuvrit uuriti?
English: What benefit has Pixuvri shown during the studies?
Estonian: Milles seisneb uuringute põhjal Pixuvri kasulikkus?
English: The medicine can only be obtained with a prescription.
Estonian: Pixuvri on retseptiravim.
English: The full EPAR and risk management plan summary for Pemetrexed medac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte ravimi Pemetrexed medac kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Pemetrexed medac is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada ravimi Pemetrexed medac võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Pemetrexed medac?
Estonian: Mis meetmed võetakse, et tagada ravimi Pemetrexed medac ohutu ja efektiivne kasutamine?
English: The Committee recommended that Pemetrexed medac be approved for use in the EU.
Estonian: Komitee soovitas ravimi Pemetrexed medac kasutamise Euroopa Liidus heaks kiita.
English: No additional studies were needed as Pemetrexed medac is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta.
Estonian: Lisauuringuid ei olnud vaja, sest Pemetrexed medac on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Alimta.
English: To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed medac.
Estonian: Kõrvalnähtude vähendamiseks tuleb patsiendil võtta kortikosteroide (põletikuvastane ravim) ja foolhapet (teatud vitamiin) ning talle tuleb ravimiga Pemetrexed medac toimuva ravi ajal süstida vitamiini B12.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pemetrexed medac, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati ravimi Pemetrexed medac omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pemetrexed medac has been shown to be comparable to Alimta.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pemetrexed medac sarnane toime ravimiga Alimta.
English: Because Pemetrexed medac is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Pemetrexed medac on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: This is a summary of the European public assessment report (EPAR) for Pemetrexed medac.
Estonian: See on ravimi Pemetrexed medac Euroopa avaliku hindamisaruande kokkuvõte.
English: This means that Pemetrexed medac is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta.
Estonian: See tähendab, et Pemetrexed medac on sarnane võrdlusravimiga Alimta, millel juba on Euroopa Liidus müügiluba.
English: Pemetrexed medac is a cancer medicine used to treat two types of lung cancer:
Estonian: Pemetrexed medac on vähiravim, mida kasutatakse kaht tüüpi kopsuvähi raviks:
English: • advanced non-small-cell lung cancer of the kind known as ‘non-squamous', where it is used either in combination with cisplatin in previously untreated patients or on its own in patients who have previously received cancer treatment.
Estonian: • kaugelearenenud mitteväikerakk-kopsuvähi muu kui lamerakuline vorm, kusjuures ravimit kasutatakse varem ravimata patsientidel koos tsisplatiiniga ja ainsa ravimina patsientidel, kes on varem saanud vähiravi.
English: For practical information about using Pemetrexed medac, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Pemetrexed medac kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: When Pemetrexed medac is given with cisplatin, an ‘anti-emetic' medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose.
Estonian: Kui ravimit Pemetrexed medac kasutatakse koos tsisplatiiniga, tuleb enne või pärast tsisplatiini annuse manustamist anda antiemeetikumi (oksendamise ennetamiseks) ja vedelikke (dehüdratsiooni ennetamiseks).
English: What is Pemetrexed medac and what is it used for?
Estonian: Mis on Pemetrexed medac ja milleks seda kasutatakse?
English: For more information about treatment with Pemetrexed medac, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Pemetrexed medac toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Pemetrexed medac pemetrexed
Estonian: Pemetrexed medac pemetrekseed
English: Pemetrexed medac is a ‘generic medicine'.
Estonian: Pemetrexed medac on geneeriline ravim.
English: It is not intended to provide practical advice on how to use Pemetrexed medac.
Estonian: Hindamisaruandes ei anta ravimi Pemetrexed medac kasutamise praktilisi nõuandeid.
English: Other information about Pemetrexed medac
Estonian: Muu teave ravimi Pemetrexed medac kohta
English: The active substance in Pemetrexed medac, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites'.
Estonian: Pemetrexed medaci toimeaine pemetrekseed on antimetaboliitide rühma kuuluv tsütotoksiline ravim (ravim, mis hävitab poolduvaid rakke, näiteks vähirakke).
English: Why is Pemetrexed medac approved?
Estonian: Miks Pemetrexed medac heaks kiideti?
English: It is given once every three weeks as an infusion lasting 10 minutes.
Estonian: Ravimit Pemetrexed medac manustatakse iga kolme nädala järel 10-minutilise infusioonina.
English: Pemetrexed medac contains the active substance pemetrexed.
Estonian: Pemetrexed medac sisaldab toimeainena pemetrekseedi.
English: Therefore, the CHMP's view was that, as for Alimta, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Alimta korral, ületab ravimi Pemetrexed medac kasulikkus sellega kaasnevad riskid.
English: The medicine can only be obtained with a prescription and should only be given under the supervision of a doctor who is qualified in the use of chemotherapy.
Estonian: Pemetrexed medac on retseptiravim ja seda tohib manustada üksnes keemiaravi kasutamises kogenud arsti järelevalve all.
English: It can also be used as a maintenance treatment in patients who have received a platinum-based chemotherapy.
Estonian: Ravimit Pemetrexed medac tohib kasutada ka säilitusraviks patsientidel, kes on saanud plaatinaravimitega keemiaravi.
English: Pemetrexed medac is available as a powder that is made up into a solution for infusion (drip) into a vein.
Estonian: Ravimit Pemetrexed medac turustatakse infusioonilahuse (veeni tilgutatava lahuse) pulbrina.
English: How does Pemetrexed medac work?
Estonian: Kuidas Pemetrexed medac toimib?
English: How has Pemetrexed medac been studied?
Estonian: Kuidas ravimit Pemetrexed medac uuriti?
English: How is Pemetrexed medac used?
Estonian: Kuidas ravimit Pemetrexed medac kasutatakse?
English: What are the benefits and risks of Pemetrexed medac?
Estonian: Milles seisneb ravimi Pemetrexed medac kasulikkus ja mis riskid ravimiga kaasnevad?
English: The reason for this is not known.
Estonian: Selle põhjus ei ole teada.
English: Results at week 16
Estonian: Tulemused 16. nädalal
English: Outcomes a
Estonian: Tulemused a
English: Date of last renewal: 17 November 2005
Estonian: Müügiloa viimase uuendamise kuupäev: 17.november 2005
English: Always take Agenerase exactly as your doctor has told you.
Estonian: Võtke Agenerase't alati täpselt nii, nagu arst on teile rääkinud.
English: This can sometimes lead to serious medical conditions.
Estonian: See võib mõnikord põhjustada raskeid haigusseisundeid.
English: • Other combinations
Estonian: • Muud kombinatsioonid
English: You will need to take Agenerase every day.
Estonian: Agenerase't tuleb võtta iga päev.
English: For this reason, it is very important that you inform your doctor about any changes in your health.
Estonian: Seetõttu on väga tähtis, et te informeeriksite arsti kõigist oma tervisliku seisundi muutustest.
English: Keep the container tightly closed.
Estonian: Hoida pakend tihedalt suletuna.
English: In some patients, additional factor VIII was given.
Estonian: Mõnele patsiendile manustati täiendavalt faktorit VIII.
English: Note that the background rates in comparator groups were not taken into account.
Estonian: Pange tähele, et taustandmeid võrdlusgrupis arvesse ei võetud.
English: You can still continue to develop other infections and other illnesses associated with HIV disease.
Estonian: Teil võivad jätkuvalt tekkida muud infektsioonid ja muud HIV-infektsiooniga seotud haigused.
English: Amprenavir / ritonavir (n = 80)
Estonian: Amprenaviir / ritonaviir (n = 80)
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 October 2000
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 20. oktoober 2000
English: Like all medicines, Agenerase can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka Agenerase põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: • A severe or life-threatening skin reaction (Stevens Johnson syndrome)
Estonian: • Tõsine või eluohtlik nahareaktsioon (Stevens-Johnsoni sündroom)
English: The frequency categories used are:
Estonian: Sageduse kategooriad on:
English: A causal relationship has been evoked, although the mechanism of action has not been elucidated.
Estonian: Põhjuslik seos on kindlaks tehtud, kuigi toimemehhanism ei ole selge.
English: DATE OF THE REVISION OF THE TEXT Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu
Estonian: TEKSTI LÄBIVAATAMISE KUUPÄEV Täpne informatsioon selle ravimi kohta on kättesaadav Euroopa Ravimiameti (EMEA) kodulehel http://www.emea.europa.eu/
English: You should not take more than 2400 mg per day.
Estonian: Te ei tohi võtta üle 2400 mg päevas.
English: Therefore this combination must be avoided.
Estonian: Seega peaks seda kombinatsiooni vältima.
English: Clinical experience:
Estonian: Kliiniline kogemus:
English: The clinical significance of these possible interactions is not known and has not been investigated.
Estonian: Nende võimalike koostoimete kliiniline tähtsus on teadmata ja seda ei ole uuritud.
English: Taking Agenerase with food and drink
Estonian: Agenerase võtmine koos toidu ja joogiga
English: However, the information currently available is not sufficient for determining the nature of the interaction.
Estonian: Ent hetkel olemasolevad andmed ei ole piisavad koostoime olemuse kindakstegemiseks.
English: What Agenerase looks like and contents of the pack
Estonian: Kuidas Agenerase välja näeb ja pakendi sisu
English: These capsules also contain sorbitol.
Estonian: Need kapslid sisaldavad ka sorbitooli.
English: • Headache, feeling tired
Estonian: • Peavalu, väsimus
English: The potential risk to humans is unknown.
Estonian: Võimalik risk inimesele ei ole teada.
English: These medicines are used for treating human immunodeficiency virus (HIV) infection.
Estonian: Neid ravimeid kasutatakse inimese immuunpuudulikkuse viiruse (HIV) poolt põhjustatud infektsiooni raviks.
English: SOC PI (n = 83): Indinavir / RTV (29%) Lopinavir / RTV (36%) Saquinavir / RTV(20%)
Estonian: SOC PI (n = 83): Indinaviir / RTV (29%) Lopinaviir / RTV (36%) Sakvinaviir / RTV(20%)
English: 1.0 (range 0-2)
Estonian: 1.0 (vahemik 0-2)